Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
There are unknown factors in our environment and in people's genes that raise the risk of getting pancreatic cancer. To learn about these things, researchers at Memorial Sloan Kettering Cancer Center created a Pancreatic Tumor Registry. This registry includes people with pancreatic cancer, and also people who have a strong family history of this disease.
Researchers want to find the best doses of MOMA-313 alone and with olaparib in people with cancer. The people in this study have advanced castration-resistant prostate cancer (CRPC) or pancreatic cancer. CRPC is prostate cancer that has spread and keeps growing even in the absence of hormones. Their cancers also have a genetic change called HR deficiency.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Researchers want to see if the herbal supplement Ma-Zi-Ren-Wan (MZRW) helps relieve chronic constipation in survivors of cancer. They will also see how MZRW affects the gut microbiome.
Leiomyosarcoma is a type of cancer that forms in smooth muscle. Researchers want to see if adding ADI-PEG 20 to the usual chemotherapy for leiomyosarcoma works better than chemotherapy alone. The people in this study have leiomyosarcoma that keeps growing despite treatment.
The purpose of this study is to find the highest dose of the investigational drug XL092 that can be given safely with immunotherapy drugs in people with advanced solid tumors that have come back or continued to grow despite treatment. Immunotherapy drugs boost the ability of the immune system to find and kill cancer cells.
Sacituzumab govitecan targets and destroys cells that make a protein called TROP-2. Researchers have found this protein to be expressed on mesothelioma cells. By destroying these cells, sacituzumab govitecan may help slow or stop the growth of your cancer. It is given intravenously (by vein).
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
